Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
38.55
-0.41 (-1.05%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gsk Plc ADR
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Can Pfizer and GlaxoSmithKline Beat Johnson & Johnson's RSV Vaccine?
October 17, 2021
J&J has set a high bar for its rivals.
Via
The Motley Fool
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
October 15, 2021
Companies working on sorely needed Covid treatments are innovating to keep up.
Via
Investor's Business Daily
More Chinese Trouble
October 14, 2021
A day after the consumer price rise there was another price rise for producer markets.
Via
Talk Markets
Why CureVac Stock Is Tumbling Today
October 12, 2021
The company is throwing in the towel on its first-generation COVID-19 vaccine candidate.
Via
The Motley Fool
Exposures
COVID-19
Daily Report: GlaxoSmithKline (GSK)
October 11, 2021
TalkMarkets Episode VII-6 Monday, 10/11/21 Stockpicker Star GlaxoSithKline (GSK) Healthcare Sector
Via
Talk Markets
Winners and Losers of Rising Energy Prices
October 12, 2021
Bond traders are back to work on Tuesday after taking Monday off for Columbus Day. Bonds are trading higher this morning as yields are falling slightly. Lower yields could pull...
Via
Benzinga
Why Did Ocugen Stock Skyrocket On Monday?
October 12, 2021
Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) surged almost 8.8% in Monday’s regular trading session and also gained 11.4% in the after-hours session. What...
Via
Benzinga
Biotech Stocks Are Lagging, Is It Time to Rebalance Your Healthcare Portfolio?
October 11, 2021
You may have seen that biotech stocks have been in a funk. The IBB has broken through the SMA-200 support line near $160 and it holds a perilous perch at $155, up only about 2.5% year-to-date. The IBB...
Via
Talk Markets
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
October 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...
Via
Benzinga
Exposures
COVID-19
AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial
October 11, 2021
AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease...
Via
Benzinga
Exposures
COVID-19
Here's Why 2022 Could Be a Huge Year for GlaxoSmithKline
October 11, 2021
Another big step in preventing HIV and AIDS has been taken and GlaxoSmithKline is at the forefront.
Via
The Motley Fool
Exposures
Product Safety
Perfumes Of Arabia
October 06, 2021
Downtrends do eventually run out of pessimistic steam, but it can take a while.
Via
Talk Markets
Best Pharmaceutical Stocks To Buy In 2021
October 06, 2021
The global pharmaceutical market has experienced significant growth in recent years. As of end-2020, the total global pharmaceutical market was valued at about 1.27 trillion U.S. dollars.
Via
Talk Markets
Sweet Smell Of Recovery
October 05, 2021
Markets today saw many reversals of moves by ADR companies in the course of the day, mainly because of macro changes.
Via
Talk Markets
Tesla and Merck Give Investors Some Hope
October 04, 2021
Friday’s rally appears to have lost its momentum over the weekend because stock futures are trading lower before Monday’s open. China’s troubled real estate...
Via
Benzinga
September Ends
September 30, 2021
Congress managed to pass a bipartisan short-term spending bill avoiding a crisis over the debt ceiling.
Via
Talk Markets
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
September 30, 2021
Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said...
Via
Benzinga
A Bit Of A Recovery
September 29, 2021
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week.
Via
Talk Markets
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...
Via
Benzinga
Exposures
COVID-19
ViiV Healthcare's Dovato Combo Regime Shows Encouraging Long Term Data In HIV Patients
September 29, 2021
ViiV Healthcare, a joint venture between GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi, presented three-year results ...
Via
Benzinga
ViiV In-Licenses Third-Gen HIV Targeting Compound From Shionogi
September 28, 2021
ViiV Healthcare, majority-owned by GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi, has announced an exclusive collaboration...
Via
Benzinga
GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option
September 28, 2021
The FDA has accepted and granted Priority Review to ViiV Healthcare's marketing application seeking approval for injectable cabotegravir long-acting for...
Via
Benzinga
Exposures
Product Safety
Sanofi Stops Work On Its mRNA COVID-19 Vaccine: What You Need To Know
September 28, 2021
Sanofi SA (NASDAQ: SNY) is dropping plans for its mRNA-based COVID-19 vaccine because it believes it will be too late in reaching the market, STAT news reported. Sanofi...
Via
Benzinga
Exposures
COVID-19
4 No-Brainer Pharmaceutical Stocks to Buy in October
September 27, 2021
While the resurgence of COVID-19 cases is driving the demand for vaccines, booster shots, and other related solutions, an aging population is expected to be a key growth driver for the pharmaceutical...
Via
Talk Markets
Exposures
COVID-19
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...
Via
Benzinga
Glaxo - Vir Biotech's COVID Treatment Approved In Japan
September 27, 2021
Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19...
Via
Benzinga
Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism
September 27, 2021
Sanofi SA (NASDAQ:SNY) shares traded higher by 0.4% on Mond...
Via
Benzinga
Exposures
COVID-19
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer?
September 27, 2021
A biotech working in lung and blood diseases, as well as cancer, could be acquired.
Via
Investor's Business Daily
China's Rescue Of Evergrand
September 23, 2021
The number of jobless last week was higher than the forecast, at 351,000 vs 320,000. The recovery is lagging.
Via
Talk Markets
Green Hygienics Holdings To Raise $100M Via Green Bond Offering
September 22, 2021
Hemp company Green Hygienics Holdings Inc. (OTCQB:GRYN) is ...
Via
Benzinga
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.